top of page

Company Information


AGM Notice & Proxy Statement
2021 Annual General Meeting
Polydex Pharmaceuticals Proxy Statement



Annual & Quarterly Financials
Reported June 2023
2024 First Quarter
Reported May 2023
2023 Annual Report
December 2022
2023 Third Quarter
Reported September 2022
2023 Second Quarter
Reported June 2022
2023 First Quarter
Reported May 2022 
2022 Annual Report
Reported December 2021
2022 Third Quarter
Reported September 2021
2022 Second Quarter
Reported June 2021
2022 First Quarter
Reported April 2021
2021 Annual Report
Reported December 2020
2021 Third Quarter
Reported September 2020
2021 Second Quarter
Reported June 2020
2021 First Quarter
Reported April 2020
2020 Annual Report
Reported December 2019
2020 3rd Quarter
Reported September 2019
2020 Second Quarter
Reported June 2019
2020 First Quarter
Reported May 1, 2019
2019 Annual Report
Reported December 2018
2019 Third Quarter
Reported September 2018
2019  Second Quarter
Reported June 2018
2019 First Quarter
Reported April 2018
2018  Annual Report
Reported December 2017
2018  Third Quarter
Reported September 2017
2018  Second Quarter
Reported June 2017
2018  First Quarter
Reported April 2017
2017  Annual Report
Reported December 2016
2017  Third Quarter 
Reported September 2016
2017  Second Quarter 
Reported June 2016
2017  First Quarter 
Reported April 2016
2016  Annual Report
Reported December 2015
2016  Third Quarter
Reported September 2015
2016  Second Quarter
Reported June 2015
2016   First Quarter 
Reported April 2015
2015   Annual Report
Reported December 2014
2015   Third Quarter
Reported September 2014
2015 Second Quarter
Reported June 2014
2015   First Quarter
Reported May 2014
2014   Annual Report
Reported December 2013
2014   Third Quarter
Reported September 2013
2014   Second Quarter

Polydex Pharmaceuticals Limited  is electronically quoted with OTC Markets.

Transfer Agent

Shareholder Correspondence


PO. Box 43006 

Providence RI  

USA   02940-3006


Overnight Correspondence


150 Royall St., Suite 101

Canton, MA

USA  02021


Code of Ethics

Polydex Pharmaceuticals Limited (the "Company") is committed to conducting its business in compliance with all applicable laws and regulations and in accordance with high standards of business conduct.

The Company strives to maintain the highest standards of accuracy, completeness and disclosure in its financial dealings, records and reports. These standards serve as the basis for managing the Company's business, for meeting the Company's duties to its stockholders and for maintaining compliance with financial reporting requirements.

The Company's Executive Officers and Senior Financial Officers must agree to comply with the following principles and promote and support this Code of Ethics.

For the purposes of this Code of Ethics, "Executive Officers" means the Company's executive officers as determined from time to time by the Board of Directors of the Company pursuant to Section 16 of United States Securities Exchange Act of 1934, as amended, and "Senior Financial Officers" means the Company's principal financial officer and controller or principal accounting officer, or persons performing similar functions.

The principal executive officer and each senior financial officer of the Company will adhere to and advocate the following principles and responsibilities governing his or her professional and ethical conduct, each to the best of his or her knowledge and ability.

1. Act with honesty and integrity and in an ethical manner, avoiding actual or apparent conflicts of interest in his or her personal and professional relationships.

2. Promptly disclose to the Company, through the Chief Financial Officer and the Company's Audit Committee, any material transaction or relationship that reasonably could be expected to give rise to a conflict of interest between his or her personal and professional relationships.

3. Provide full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the United States Securities and Exchange Commission, and in other public communications made by the Company.

4. Comply with applicable rules and regulations of federal, state and local governments and other appropriate private and public regulatory agencies.

5. Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing his or her independent judgment to be subordinated.

6. Use good business judgment in the processing and recording of all financial transactions.

7. Respect the confidentiality of information acquired in the course of his or her work, except when authorized or otherwise legally obligated to disclose such information, and not use confidential information acquired in the course of work for personal advantage.

8. Share knowledge and maintain skills important and relevant to his or her constituents' needs.

9. Promote ethical behavior among constituents in the work environment.

10. Achieve responsible use of and control over all assets and resources employed or entrusted to him or her.

11. Comply with generally accepted accounting standards and practices, rules, regulations and controls.

12. Ensure that accounting entries are promptly and accurately recorded and properly documented and that no accounting entry intentionally distorts or disguises the true nature of any business transaction.

13. Maintain books and records that fairly and accurately reflect the Company's business transactions.

14. Sign only those documents that he or she believes to accurate and truthful.

15. Devise, implement and maintain sufficient internal controls to assure that financial record keeping objectives are met.

16. Prohibit the establishment of any undisclosed or unrecorded funds or assets for any purpose and provide for the proper and prompt recording of all disbursements of funds and all receipts.

17. Not knowingly be a party to any illegal activity or engage in acts that are discreditable to his or her profession or the Company.

18. Respect and contribute to the legitimate and ethical objectives of the Company.

19. Engage in only those services for which he or she has the necessary knowledge, skill and expertise.

20. Not make, or tolerate to be made, false or artificial statements or entries for any purpose in the books and records of the Company or in any internal or external correspondence, memoranda, or communication of any type, including telephone or wire communications.

21. Report to the Company, through the Chief Financial Officer and the Company's Audit Committee any situation where this Code of Ethics, the Company's standards or laws are being violated.

​Those required to comply with this Code of Ethics understand that failure to comply with this Code of Ethics will not be tolerated by the Company and that deviations therefrom or violations thereof will result in serious consequences, which may include, but may not be limited to, serious reprimand, dismissal or other legal actions.​

The parties subject to this Code of Ethics will acknowledge in writing that they agree to comply with these requirements​.


bottom of page